


## Novel Inhibitors of Inflammasome

A new class of anti-inflammatory drugs and their potential to limit injury

Acute myocardial infarction (AMI) is one of the leading causes of adverse cardiac remodeling, heart failure, and death worldwide. Cryopyrin has been shown to play a major role in the formation of the inflammasome in the heart during AMI and its potential inhibitors could be used to prevent adverse cardiac remodeling after AMI. There is an urgent need for new therapeutic strategies specifically aimed at modulating inflammation during AMI. The current approach of reperfusion and inhibition of neurohormonal activation has successfully reduced morbidity and mortality of AMI, but is still associated with unacceptably high incidence of heart failure and death that may be related to the excessive inflammatory activity. Glyburide is an anti-diabetic drug shown to also inhibit cryopyrin, but the need for high doses causes severe hypoglycemia and has been shown to be cardiotoxic.

### The technology

This invention presents a new class of anti-inflammatory drugs and their potential to limit cardiac injury due to a sterile inflammation during AMI and prevent heart failure through inhibition of the cryopyrin inflammasome. Dr. Abbate and colleagues from Virginia Commonwealth University have designed and investigated several glyburide analogs that are chemically stable, show lower toxicity, and specifically inhibit cryopyrin inflammasome without affecting glucose metabolism. The figure below demonstrates one of the compounds (GA2) inhibiting activity. Such inflammasome inhibitors may prove useful not only for treatment of AMI, but also in other inflammasome-mediated diseases such as diabetes, gout, and auto-inflammatory diseases.



### Benefits

- » Lower toxicity due to low doses
- » Better solubility
- » Wide range of applications

### Applications

- » Acute myocardial infarction and ischemia
- » Diabetes
- » Cancer
- » Gout and auto-inflammatory diseases

#### Patent status:

US rights available.  
Patent Issued: [U.S.10,343,985](#)

#### License status:

This technology is available for licensing to industry for further development and commercialization.

#### Category:

Biomedical

#### VCU Tech #:

13-031

#### Investigators:

Antonio Abbate  
Shijun Zhang  
Benjamin Van Tassell

#### External Resources:

[Abbate et al. 2014](#)

#### Contact us about this technology

Magdalena K. Morgan, Ph.D.  
Assistant Director  
mkmorgan@vcu.edu  
(804) 827-6095